Argent BioPharma has raised US$4.5 million (A$7.3m) through the placement of 11,250,000 shares at US$0.40c (A$0.65c) each, with the proceeds earmarked to advance the firm’s drug development pipeline.
A particular focus will be on progressing Argent’s CannEpil epilepsy treatment and planned clinical studies.
The company is also conducting a strategic review to ensure the long-term sustainability of its operations, following its delisting from the London Stock Exchange, with plans to list in the US.
Greenfern Industries
Greenfern Industries (GFI) has secured a six-month loan facility of NZ$200k plus fees and interest from Emdex Limited.
GFI told the NZX the loan will provide short-term funding to support its ongoing operations and strategic initiatives.
Meanwhile, the firm is set to hold a special shareholder meeting to vote on various related party loans and agreements in the coming weeks.